Protagonist Therapeutics (PTGX) Interest & Investment Income (2015 - 2026)
Protagonist Therapeutics (PTGX) reported Interest & Investment Income of $5.9 million for Q1 2026, down 22.41% on a YoY basis from $7.6 million in Q1 2025, and down 13.09% sequentially from $6.8 million in Q4 2025.
Protagonist Therapeutics (PTGX) Interest & Investment Income (2015 - 2026) Analysis & Trends
Protagonist Therapeutics (PTGX) has 12 years of Interest & Investment Income data on file, last reported at $5.9 million in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income fell 22.41% year-over-year to $5.9 million; the trailing twelve-month figure through Mar 2026 stood at $27.1 million (down 8.2% YoY), and the FY2025 full-year result was $28.8 million, up 9.4% from the prior year.
- Interest & Investment Income retreated to $5.9 million in Q1 2026, from $6.8 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $7.7 million in Q3 2024 to a low of $168000.0 in Q1 2022.
- A 5-year average of $4.7 million and a median of $4.4 million in 2024 frame the typical range for Interest & Investment Income.
- Across the five-year window, Interest & Investment Income jumped 1745.08% in 2022 and declined 22.41% in 2026, its largest moves.
- Tracing PTGX's Interest & Investment Income over 5 years: stood at $2.3 million in 2022, then surged by 88.45% to $4.2 million in 2023, then jumped by 61.55% to $6.9 million in 2024, then decreased by 1.34% to $6.8 million in 2025, then dropped by 13.09% to $5.9 million in 2026.
- Business Quant data shows PTGX's Interest & Investment Income at $5.9 million in Q1 2026, $6.8 million in Q4 2025, and $7.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Protagonist Therapeutics | 8.86 Bn | 8.86 Bn | - | 5.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.88 Mn |
| Dec 31, 2025 | 6.76 Mn |
| Sep 30, 2025 | 7.05 Mn |
| Jun 30, 2025 | 7.41 Mn |
| Mar 31, 2025 | 7.57 Mn |
| Dec 31, 2024 | 6.85 Mn |
| Sep 30, 2024 | 7.68 Mn |
| Jun 30, 2024 | 7.40 Mn |
| Mar 31, 2024 | 4.38 Mn |
| Dec 31, 2023 | 4.24 Mn |
| Sep 30, 2023 | 4.25 Mn |
| Jun 30, 2023 | 3.91 Mn |
| Mar 31, 2023 | 2.49 Mn |
| Dec 31, 2022 | 2.25 Mn |
| Sep 30, 2022 | 1.16 Mn |
| Jun 30, 2022 | 484,000.00 |
| Mar 31, 2022 | 168,000.00 |
| Dec 31, 2021 | 122,000.00 |
| Sep 30, 2021 | 122,000.00 |
| Jun 30, 2021 | 97,000.00 |